Literature DB >> 15843519

B lymphocytes participate in cross-presentation of antigen following gene gun vaccination.

Huiming Hon1, Alp Oran, Thomas Brocker, Joshy Jacob.   

Abstract

Although endocytosed proteins are commonly presented via the class II MHC pathway to stimulate CD4(+) T cells, professional APCs can also cross-present Ags, whereby these exogenous peptides can be complexed with class I MHC for cross-priming of CD8(+) T cells. Whereas the ability of dendritic cells (DCs) to cross-present Ags is well documented, it is not known whether other APCs may also play a role, or what is the relative contribution of cross-priming to the induction of acquired immunity after DNA immunization. In this study, we compared immune responses generated after gene gun vaccination of mice with DNA vaccine plasmids driven by the conventional CMV promoter, the DC-specific CD11c promoter, or the keratinocyte-specific K14 promoter. The CD11c promoter achieved equivalent expression in CD11c(+) DCs in draining lymph nodes over time, as did a conventional CMV-driven plasmid. However, immunization with DC-restricted DNA vaccines failed to generate protective humoral or cellular immunity to model Ags influenza hemagglutinin and OVA, despite the ability of CD11c(+) cells isolated from lymph nodes to stimulate proliferation of Ag-specific T cells directly ex vivo. In contrast, keratinocyte-restricted vaccines elicited comparable T and B cell activity as conventional CMV promoter-driven vaccines, indicating that cross-priming plays a major role in the generation of immune responses after gene gun immunization. Furthermore, parallel studies in B cell-deficient mu-MT mice demonstrated that B lymphocytes, in addition to DCs, mediate cross-priming of Ag-specific T cells. Collectively, these data indicate that broad expression of the immunogen is required for optimal induction of protective acquired immunity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15843519     DOI: 10.4049/jimmunol.174.9.5233

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  37 in total

1.  Transgene expression and local tissue distribution of naked and polymer-condensed plasmid DNA after intradermal administration in mice.

Authors:  R Noelle Palumbo; Xiao Zhong; David Panus; Wenqing Han; Weihang Ji; Chun Wang
Journal:  J Control Release       Date:  2012-01-24       Impact factor: 9.776

2.  Uptake and presentation of exogenous antigen and presentation of endogenously produced antigen by skin dendritic cells represent equivalent pathways for the priming of cellular immune responses following biolistic DNA immunization.

Authors:  Stephan Sudowe; Sabine Dominitzki; Evelyn Montermann; Matthias Bros; Stephan Grabbe; Angelika B Reske-Kunz
Journal:  Immunology       Date:  2008-09-17       Impact factor: 7.397

Review 3.  Antigen cross-presentation: extending recent laboratory findings to therapeutic intervention.

Authors:  T W H Flinsenberg; E B Compeer; J J Boelens; M Boes
Journal:  Clin Exp Immunol       Date:  2011-05-11       Impact factor: 4.330

Review 4.  B cells in chronic graft-versus-host disease.

Authors:  Stefanie Sarantopoulos; Bruce R Blazar; Corey Cutler; Jerome Ritz
Journal:  Biol Blood Marrow Transplant       Date:  2014-11-12       Impact factor: 5.742

Review 5.  The role of B cells and humoral immunity in Mycobacterium tuberculosis infection.

Authors:  John Chan; Simren Mehta; Sushma Bharrhan; Yong Chen; Jacqueline M Achkar; Arturo Casadevall; JoAnne Flynn
Journal:  Semin Immunol       Date:  2014-10-28       Impact factor: 11.130

Review 6.  DNA vaccines for prostate cancer.

Authors:  Christopher D Zahm; Viswa Teja Colluru; Douglas G McNeel
Journal:  Pharmacol Ther       Date:  2017-02-07       Impact factor: 12.310

7.  Mini-intronic plasmid vaccination elicits tolerant LAG3+ CD8+ T cells and inferior antitumor responses.

Authors:  Viswa Teja Colluru; Christopher D Zahm; Douglas G McNeel
Journal:  Oncoimmunology       Date:  2016-09-02       Impact factor: 8.110

Review 8.  Developing T-cell therapies for lymphoma without receptor engineering.

Authors:  Melanie Grant; Catherine M Bollard
Journal:  Blood Adv       Date:  2017-12-08

9.  Immunization with a lentivector that targets tumor antigen expression to dendritic cells induces potent CD8+ and CD4+ T-cell responses.

Authors:  Luciene Lopes; Marie Dewannieux; Uzi Gileadi; Ranbir Bailey; Yasuhiro Ikeda; Christopher Whittaker; Matthew P Collin; Vincenzo Cerundolo; Mizuki Tomihari; Kiyoshi Ariizumi; Mary K Collins
Journal:  J Virol       Date:  2007-10-24       Impact factor: 5.103

Review 10.  How B cells shape the immune response against Mycobacterium tuberculosis.

Authors:  Paul J Maglione; John Chan
Journal:  Eur J Immunol       Date:  2009-03       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.